The latest CDC numbers show a 5.0% increase of measles cases from week-to-week. The US total reached 4,080 confirmed cases, 78% above all of 2025.
|Articles|January 24, 2022
Most COVID-19 Patients Admitted to ICU Still Experience Symptoms 1 Year Later
Author(s)Nina Cosdon
Nearly 75% of COVID-19 patients admitted to the ICU were symptomatic 1 year later, most commonly reporting weakened condition and musculoskeletal problems.
Advertisement
The COVID-19 pandemic caused many patients to fall critically ill and require treatment in an intensive care unit (ICU). Even a year later, the ICU patients who survived COVID-19 commonly experience physical, mental, and cognitive symptoms.
The exploratory prospective multicenter cohort study was conducted in the ICUs of 11 Dutch hospitals and published today in the
The main outcomes were physical symptoms (including frailty, fatigue, and other physical problems), mental symptoms (anxiety, depression, PTSD), and cognitive symptoms self-reported 1 year after ICU treatment.
Of the initial patient cohort, 301 (66.8%) were included in the study. The average age was 61.2 years, the average duration of ICU stay was 18 days, and 71.5% were male. A year after their release from the ICU, 74.3% of patients reported physical symptoms, 26.2% reported mental symptoms, and 16.2% reported cognitive symptoms.
The most commonly reported new physical problems were weakened condition (38.9%), joint stiffness (26.3%), joint pain (25.5%), muscle weakness (24.8%), and myalgia (21.3%).
The respondents indicated that their continued COVID-19 symptoms make it difficult to go about their day-to-day lives, with 58% of ICU survivors saying they had problems returning to work.
This frequency of symptoms 1 year after recovering from severe COVID-19 disease is concerning, as much is still unknown about “long covid” and the long-term health impact of COVID-19 infection.
Advertisement
Related to this article
With US measles cases nearing 3,900 this year and Pennsylvania reporting its fifth measles-related death, here is a review of how the virus spreads, how it is prevented and managed, and what severe disease looks like.
Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate met every prespecified primary immunogenicity and safety endpoint against PCV20 and PCV21 in the OPUS-1 trial of 4,047 US adults.
Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.